Business
Radiopharm Theranostics tanks on ASX debut – The Australian Financial Review
The paper value of chairman Paul Hopper’s 35.5 per cent stake fell from $54 million to $36 million in just a few hours.
The early stage company does not have revenue from licence arrangements or product sales. It is developing a platform of radiopharmaceutical products for diagnostic and therapeutic cancer treatment.
Shanghai-based NanoMab Technologies is the second-largest…
Continue Reading
-
Noosa News21 hours agoFlatmates of missing teen Pheobe Bishop, 17, identified
-
Noosa News23 hours agoTully Sugar Mill celebrates 100 years of cane harvesting amid floods and cyclones
-
Noosa News19 hours agoFranz Ferdinand: Australian Tour 2025
-
General20 hours agoPostecoglou’s message touches Blues AFL coach Voss after Spurs’ Europa League win